NATCO Pharma Ltd on Monday announced that its partner Mylan Pharmaceuticals Inc has reached a patent litigation settlement with Novo Nordisk in the US over generic Ozempic, a drug used to lower blood sugar and weight loss.
According to a report by news agency PTI, NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products, the company said in a regulatory filing. Ozempic is a prescription medication patented by Novo Nordisk.
“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide),” NATCO said in the filing. The terms of the settlement are confidential, it added.
Novo Nordisk had filed a patent infringement suit against Mylan over Ozempic in a US court.
(With inputs from PTI)
